health Back to content The Hearing Aids business area is instrumental to Demant in realising all our ambitions for our core contribution to global health and sustainable development. Our research and development activities in-house and through collaborations with academia and peers not only allow our users access to innovative technologies now and in the future, but they contribute with significant results to hearing research for the benefit of the global hearing health community. Our continued active engagement in European Instrument Manufacturers Association (EHIMA) compliments our efforts to raise awareness of healthy hearing, prevention and treatment of hearing loss. In terms of our ambition to improve the hearing health infra- structure in countries with less developed hearing healthcare systems, we are currently exploring new partnerships that we deem necessary to advance this agenda. We aim to report the updates of this ambition in our 2022 report. The following highlights research and development activities in 2021, including Oticon’s research centre Eriksholm. Results Target met. Target not met. Target met. 2022 Targets Investigate benefit of well-treated hearing loss among children. Explore new methods. Final data analysis. Conclude on BEAR. Demant ∙ Sustainability Report 2021 48
Download PDF file